<DOC>
	<DOCNO>NCT01231503</DOCNO>
	<brief_summary>The aim malaria vaccine program MVI/GSK partnership develop efficacious malaria vaccine deliverable exist system , Expanded Program Immunization ( EPI ) WHO . This study design : - Investigate safety immunogenicity 7 infant immunization schedule experimental malaria vaccine integrate EPI regimen . - Investigate maximize antibody response experimental malaria vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity GSK Biologicals ' Malaria Vaccine 257049 When Administered 7 Schedules African Infants</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry : A male female infant 1 7 day ( inclusive ) age ( day 1 day birth ) . Signed thumbprinted informed consent obtain parent ( ) /guardian ( ) child . Where parent ( ) /guardian ( ) illiterate , consent form countersign witness . Subjects investigator believe parents/guardians comply requirement protocol ( e.g . return followup visit ) enrol study . Born mother negative HIV antibody Hepatitis B surface antigen . Subjects born normal gestation period ( 37 42 week ) ( Gestational age determine carry clinical assessment infant accord principle set Dubowitz ( 1970 ) first 5 day life ) . A minimum weight 2.5 kg . The following criterion check time study entry . If apply , subject must include study : Acute chronic illness determine clinical physical examination laboratory screen test include , limited : Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . Major congenital defect . History neurological disorder seizure . Laboratory screen test normal ranges/limits define per protocol . Previous vaccination diphtheria , tetanus , pertussis ( wholecell acellular ) , Hemophilus influenzae type b , hepatitis B , BCG tuberculosis , measles oral polio vaccine . Planned administration/administration license vaccine ( i.e . vaccine approve one follow authority : FDA EU member state WHO [ respect prequalification ] ) foreseen study protocol within 7 day first dose study vaccine . Administration immunoglobulins , blood transfusion blood product since birth first dose study vaccine plan administration study period . Use drug vaccine approve indication ( one follow authority : FDA EU member state WHO [ respect prequalification ] ) study vaccine start birth plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . Simultaneous participation clinical trial . Samesex twin ( avoid misidentification ) . Maternal death . History allergic reaction ( significant IgEmediated event ) anaphylaxis previous immunization . History allergic disease reaction likely exacerbate component vaccine . Children enrol maternal , obstetrical neonatal event occur might , judgment investigator , result increase neonatal/infant morbidity Any finding investigator feel would increase risk adverse outcome participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>7 Days</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Africa</keyword>
	<keyword>malaria vaccine</keyword>
	<keyword>schedule</keyword>
	<keyword>EPI</keyword>
	<keyword>Plasmodium falciparum</keyword>
</DOC>